Biomarker assessment and molecular testing for prognostication in breast cancer

Histopathology

Volumn 68, Issue 1, 2016, Pages 70-85

  Kos, Zuzana ^a   Dabbs, David J ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Breast; ErbB 2; Gene expression profiling; Neoplasm; Oestrogen; Progesterone; Prognosis; Receptors; Transcriptome

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INTERLEUKIN 17; KI 67 ANTIGEN; PERTUZUMAB; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER; ERBB2 PROTEIN, HUMAN;

BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CARDIOTOXICITY; DNA MICROARRAY; DNA MICROARRAY KIT; DRUG COST; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION SYSTEM; PRIORITY JOURNAL; REVIEW; BREAST TUMOR; FEMALE; GENE EXPRESSION PROFILING; METABOLISM; MOLECULAR PATHOLOGY; PATHOLOGY; PROGNOSIS;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KI-67 ANTIGEN; PATHOLOGY, MOLECULAR; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84954565048     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12795     Document Type: Review

References (132)

1. McGuire WL. Estrogen receptors in human breast cancer. J. Clin. Invest. 1973; 52; 73-77.
2. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406; 747-752.
3. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. 2001; 98; 10869-10874.
4. Heldring N, Pike A, Andersson S et al. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 2007; 87; 905-931.
5. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896; 148; 162-165.
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365; 1687-1717.
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351; 1451-1467.
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378; 771-784.
9. Davies C, Pan H, Godwin J et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381; 805-816.
10. Gray RG, Rea D, Handley K et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6, 953 women with early breast cancer. J. Clin. Oncol. 2013; 31(Suppl.); abstract 5.
11. Burstein HJ, Temin S, Anderson H et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused update. J. Clin. Oncol. 2014; 32; 2255-2269.
12. Senkus E, Kyriakides S, Penault-Llorca F et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013; 24(Suppl. 6); vi7-vi23.
13. Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors a study of preoperative treatment. Clin. Cancer Res. 2004; 10; 6622-6628.
14. Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br. J. Cancer 2004; 91; 2012-2017.
15. Hammond MEH, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 2010; 28; 2784-2795.
16. Khoshnoud MR, Löfdahl B, Fohlin H et al. Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Res. Treat. 2010; 126; 421-430.
17. Iwamoto T, Booser D, Valero V et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J. Clin. Oncol. 2012; 30; 729-734.
18. Rakha EA, Lee AHS, Roberts J et al. Low-estrogen receptor-positive breast cancer: the impact of tissue sampling, choice of antibody, and molecular subtyping. J. Clin. Oncol. 2012; 30; 2929-2930.
19. Hagan CR, Lange CA. Molecular determinants of context-dependent progesterone receptor action in breast cancer. BMC Med. 2014; 12; 32.
20. Knutson TP, Daniel AR, Fan D et al. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res. 2012; 14; R95.
21. Lange CA. Challenges to defining a role for progesterone in breast cancer. Steroids 2008; 73; 914-921.
22. Chlebowski RT, Hendrix SL, Langer RD et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289; 3243-3253.
23. LaCroix AZ, Chlebowski RT, Manson JE et al. Health risks and benefits after stopping the Women's Health Initiative Trial of Conjugated Equine Estrogens in postmenopausal women with prior hysterectomy. JAMA 2011; 305; 1305-1314.
24. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362; 419-427.
25. Viale G, Regan MM, Maiorano E et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J. Clin. Oncol. 2007; 25; 3846-3852.
26. Dowsett M, Houghton J, Iden C et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann. Oncol. 2006; 17; 818-826.
27. Bardou V-J, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 2003; 21; 1973-1979.
28. Fernö M, Stål O, Baldetorp B et al. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Res. Treat. 2000; 59; 69-76.
29. Maeyer LD, Limbergen EV, Nys KD et al. Does estrogen receptor-negative/progesterone receptor-breast carcinoma exist? J. Clin. Oncol. 2008; 26; 335-336.
30. Hefti MM, Hu R, Knoblauch NW et al. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res. 2013; 15; R68.
31. Cserni G, Francz M, Kálmán E et al. Estrogen receptor negative and progesterone receptor positive breast carcinomas - how frequent are they? Pathol. Oncol. Res. 2011; 17; 663-668.
32. Pichon M-F, Pallud C, Brunet M, Milgrom E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res. 1980; 40; 3357-3360.
33. Prat A, Cheang MCU, Martín M et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J. Clin. Oncol. 2013; 31; 203-209.
34. Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 2013; 24; 2206-2223.
35. Lamy P-J, Pujol P, Thezenas S et al. Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy. Breast Cancer Res. Treat. 2002; 76; 65-71.
36. Ravdin PM, Green S, Dorr TM et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J. Clin. Oncol. 1992; 10; 1284-1291.
37. Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell. Mol. Life Sci. 2008; 65; 1566-1584.
38. Pegram MD, Konecny G, Slamon DJ. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. In Gradishar WJ, Wood WC eds. Advances in breast cancer management. 2nd ed. New York, NY: Springer, 2000; 57-75.
39. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235; 177-182.
40. Cheang MCU, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 2008; 14; 1368-1376.
41. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N. Engl. J. Med. 2001; 344; 783-792.
42. Perez EA, Romond EH, Suman VJ et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J. Clin. Oncol. 2011; 29; 3366-3373.
43. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369; 29-36.
44. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 2011; 365; 1273-1283.
45. Wolff AC, Hammond MEH, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 2007; 131; 18-43.
46. Wolff AC, Hammond MEH, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 2013; 31; 3997-4013.
47. Swain SM, Baselga J, Kim S-B et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 2015; 372; 724-734.
48. Gerdes J, Li L, Schlueter C et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am. J. Pathol. 1991; 138; 867-873.
49. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010; 11; 174-183.
50. Ellis MJ, Coop A, Singh B et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 2003; 63; 6523-6531.
51. Ellis MJ, Suman VJ, Hoog J et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical andbiomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031. J. Clin. Oncol. 2011; 29; 2342-2349.
52. Smith IE, Walsh G, Skene A et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J. Clin. Oncol. 2007; 25; 3816-3822.
53. Dowsett M, Bundred NJ, Decensi A et al. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol. Biomark. Prev. 2001; 10; 961-966.
54. Guix M, Granja Nde M, Meszoely I et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J. Clin. Oncol. 2008; 26; 897-906.
55. Robertson JF, Nicholson RI, Bundred NJ et al. Comparison of the short-term biological effects of 7alpha-[9-(4, 4, 5, 5, 5-pentafluoropentylsulfinyl)-nonyl]estra-1, 3, 5, (10)-triene-3, 17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001; 61; 6739-6746.
56. Ellis MJ, Tao Y, Luo J et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J. Natl Cancer Inst. 2008; 100; 1380-1388.
57. Dowsett M, Smith IE, Ebbs SR et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl Cancer Inst. 2007; 99; 167-170.
58. Dowsett M, Smith I, Robertson J et al. Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. J. Natl. Cancer Inst. Monogr. 2011; 2011; 120-123.
59. Dowsett M, Nielsen TO, A'Hern R et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J. Natl Cancer Inst. 2011; 103; 1656-1664.
60. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007; 25; 5287-5312.
61. Polley M-YC, Leung SCY, McShane LM et al. An international Ki67 reproducibility study. J. Natl Cancer Inst. 2013; 105; 1897-1906.
62. Mikami Y, Ueno T, Yoshimura K et al. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 ring study. Cancer Sci. 2013; 104; 1539-1543.
63. Varga Z, Diebold J, Dommann-Scherrer C et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS ONE 2012; 7; e37379.
64. Polley M-YC, Leung SCY, Gao D et al. An international study to increase concordance in Ki67 scoring. Mod. Pathol. 2015; 28; 778-786.
65. Hitchman E, Hodgkinson C, Roberts D et al. Effect of prolonged formalin fixation on immunohistochemical staining for the proliferation marker Ki67. Histopathology 2011; 59; 1261-1263.
66. Wester K, Andersson AC, Ranefall P, Bengtsson E, Malmström PU, Busch C. Cultured human fibroblasts in agarose gel as a multi-functional control for immunohistochemistry. Standardization of Ki67 (MIB1) assessment in routinely processed urinary bladder carcinoma tissue. J. Pathol. 2000; 190; 503-511.
67. Mengel M, von Wasielewski R, Wiese B, Rüdiger T, Müller-Hermelink HK, Kreipe H. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J. Pathol. 2002; 198; 292-299.
68. Munakata S, Hendricks JB. Effect of fixation time and microwave oven heating time on retrieval of the Ki-67 antigen from paraffin-embedded tissue. J. Histochem. Cytochem. 1993; 41; 1241-1246.
69. Sato M, Kojima M, Nagatsuma AK, Nakamura Y, Saito N, Ochiai A. Optimal fixation for total preanalytic phase evaluation in pathology laboratories. A comprehensive study including immunohistochemistry, DNA, and mRNA assays. Pathol. Int. 2014; 64; 209-216.
70. Cuzick J, Dowsett M, Pineda S et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J. Clin. Oncol. 2011; 29; 4273-4278.
71. Focke CM, Gläser D, Finsterbusch K et al. Interlaboratory variability of Ki67 labeling index in breast cancer tissue microarrays. Cancer Res. 2013; 73(Suppl. 24); P3-P05.
72. Barton S, Zabaglo L, A'Hern R et al. Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. Br. J. Cancer 2012; 106; 1760-1765.
73. Yeo BJ, Dowsett M, Smith IE, Zabaglo L. The clinical impact of using the IHC4 score: our MDT experience in a prospective series of postmenopausal women with ER positive early breast cancer. Ann. Oncol. 2014; 25(Suppl. 1); i2.
74. Klein ME, Dabbs DJ, Shuai Y et al. Prediction of the oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod. Pathol. 2013; 26; 658-664.
75. Turner BM, Skinner KA, Tang P et al. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. Mod. Pathol. 2015; 28; 921-931.
76. Van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415; 530-536.
77. Van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002; 347; 1999-2009.
78. Institute of Medicine, Micheel CM, Nass SJ, Omenn GS eds. Evolution of translational omics: lessons learned and the path forward. Washington, DC: National Academies Press; 2012.
79. Buyse M, Loi S, van't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 2006; 98; 1183-1192.
80. Bueno-de-Mesquita JM, van Harten WH, Retel VP et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol. 2007; 8; 1079-1087.
81. Bueno-de-Mesquita JM, Linn SC, Keijzer R et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res. Treat. 2009; 117; 483-495.
82. Mook S, Schmidt MK, Weigelt B et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann. Oncol. 2010; 21; 717-722.
83. Mook S, Schmidt MK, Viale G et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res. Treat. 2009; 116; 295-302.
84. Drukker CA, Bueno-de-Mesquita JM, Retèl VP et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int. J. Cancer 2013; 133; 929-936.
85. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004; 351; 2817-2826.
86. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 2006; 24; 3726-3734.
87. Ioannidis JPA. Is molecular profiling ready for use in clinical decision making? Oncologist 2007; 12; 301-311.
88. Schmidt M, Untch M. Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer - a problem still to be solved. Ann. Oncol. 2014; 25; 754.
89. Dowsett M, Cuzick J, Wale C et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J. Clin. Oncol. 2010; 28; 1829-1834.
90. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010; 11; 55-65.
91. Goldstein LJ, Gray R, Badve S et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J. Clin. Oncol. 2008; 26; 4063-4071.
92. Habel LA, Shak S, Jacobs MK et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006; 8; R25.
93. Kelly CM, Krishnamurthy S, Bianchini G et al. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 2010; 116; 5161-5167.
94. Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol. 2008; 4; 603-610.
95. Gonzalez-Angulo AM, Barlow WE, Gralow JR et al. OT1-03-01: a randomized Phase III clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients (pts) with 1-3 positive nodes, hormone receptor (HR)-positive and HER2-negative breast cancer with recurrence score (RS) of 25 or less: SWOG S1007. Cancer Res. 2011; 71(Suppl. 24); OT1-03-01.
96. Dabbs DJ, Klein ME, Mohsin SK, Tubbs RR, Shuai Y, Bhargava R. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the oncotype DX test: an independent quality assurance study. J. Clin. Oncol. 2011; 29; 4279-4285.
97. Christgen M, Harbeck N, Gluz O, Nitz U, Kreipe HH. Recognition and handling of discordant negative human epidermal growth factor receptor 2 classification by oncotype DX in patients with breast cancer. J. Clin. Oncol. 2012; 30; 3313-3314.
98. Dvorak L, Dolan M, Fink J, Varghese L, Henriksen J, Gulbahce HE. Correlation between HER2 determined by fluorescence in situ hybridization and reverse transcription-polymerase chain reaction of the oncotype DX test. Appl. Immunohistochem. Mol. Morphol. 2013; 21; 196-199.
99. Park MM, Ebel JJ, Zhao W, Zynger DL. ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment. Breast J. 2014; 20; 37-45.
100. Parker JS, Mullins M, Cheang MCU et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009; 27; 1160-1167.
101. Cheang MCU, Voduc KD, Tu D et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin. Cancer Res. 2012; 18; 2402-2412.
102. Chia SK, Bramwell VH, Tu D et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin. Cancer Res. 2012; 18; 4465-4472.
103. Bastien RRL, Rodríguez-Lescure Á, Ebbert MTW et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med. Genomics 2012; 5; 44.
104. Nielsen TO, Parker JS, Leung S et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin. Cancer Res. 2010; 16; 5222-5232.
105. Geiss GK, Bumgarner RE, Birditt B et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol. 2008; 26; 317-325.
106. Dowsett M, Sestak I, Lopez-Knowles E et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J. Clin. Oncol. 2013; 31; 2783-2790.
107. Sestak I, Dowsett M, Zabaglo L et al. Factors predicting late recurrence for estrogen receptor-positive breast cancer. J. Natl Cancer Inst. 2013; 105; 1504-1511.
108. Gnant M, Filipits M, Greil R et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann. Oncol. 2014; 25; 339-345.
109. Filipits M, Nielsen TO, Rudas M et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin. Cancer Res. 2014; 20; 1298-1305.
110. Nielsen T, Wallden B, Schaper C et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer 2014; 14; 177.
111. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst. 2006; 98; 262-272.
112. Loi S, Haibe-Kains B, Desmedt C et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol. 2007; 25; 1239-1246.
113. Toussaint J, Sieuwerts AM, Haibe-Kains B et al. Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genom. 2009; 10; 424.
114. Ma X-J, Salunga R, Dahiya S et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin. Cancer Res. 2008; 14; 2601-2608.
115. Jankowitz RC, Cooper K, Erlander MG et al. Prognostic utility of the breast cancer index and comparison to adjuvant! Online in a clinical case series of early breast cancer. Breast Cancer Res. 2011; 13; R98.
116. Sgroi DC, Sestak I, Cuzick J et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013; 14; 1067-1076.
117. Filipits M, Rudas M, Jakesz R et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 2011; 17; 6012-6020.
118. Martin M, Brase JC, Calvo L et al. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Res. 2014; 16; R38.
119. Dubsky P, Brase JC, Jakesz R et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br. J. Cancer 2013; 109; 2959-2964.
120. Kronenwett R, Bohmann K, Prinzler J et al. Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. BMC Cancer 2012; 12; 456.
121. Denkert C, Kronenwett R, Schlake W et al. Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch. 2012; 460; 251-259.
122. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat. Clin. Pract. Oncol. 2005; 2; 416-422.
123. Biganzoli E, Boracchi P, Marubini E. Biostatistics and tumor marker studies in breast cancer: design, analysis and interpretation issues. Int. J. Biol. Markers 2003; 18; 40-48.
124. Simon R. Evaluating prognostic factor studies. TNM Online. 2003. doi: 10.1002/0471463736.tnmp04.
125. Gazinska P, Grigoriadis A, Brown JP et al. Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. Mod. Pathol. 2013; 26; 955-966.
126. Gucalp A, Tolaney S, Isakoff SJ et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin. Cancer Res. 2013; 19; 5505-5512.
127. Emens LA, Braiteh FS, Cassier P et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Cancer Res. 2015; 75(Suppl. 9); PD1-PD6.
128. Hassett MJ, Silver SM, Hughes ME et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J. Clin. Oncol. 2012; 30; 2218-2226.
129. Eiermann W, Rezai M, Kümmel S et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann. Oncol. 2013; 24; 618-624.
130. Cusumano PG, Generali D, Ciruelos E et al. European inter-institutional impact study of MammaPrint. Breast 2014; 23; 423-428.
131. Drukker CA, van den Hout HC, Sonke GS et al. Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature. Eur. J. Cancer 2014; 50; 1045-1054.
132. Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Inst. 2009; 101; 736-750.